The benefit of cancer chemotherapy based on alkylating agents is limited because of the
action of DNA repair enzymes, which mitigate the damage induced by these agents. The …

Introduction ROS1-rearranged (ROS1+) non-small-cell lung cancer (NSCLC) is a rare lung
cancer with limited treatment options. Phase I-II studies with ROS1-tyrosine kinase inhibitors (…

Nucleotide excision repair ( NER ) is involved in the repair of DNA damage caused by
platinum derivatives and has been shown to decrease the cytotoxic activity of these drugs. …

Trastuzumab is a monoclonal antibody already approved in the treatment of HER2-expressing
breast cancer. Despite its efficacy, resistance often occurs. Here, we investigated the …

Background Benefit from maintenance in advanced non-squamous non-small cell lung
cancer (NS-NSCLC) might favor switch maintenance after disease stabilization (SD) and …

Discussion M. bovis BJI is a rare clinical condition. Out of 7936 tuberculosis cases reported
over a 17-year period in Denmark, 282 (3.6%) presented with a probable skeletal localization…

Background Anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non–small cell lung
cancer (NSCLC) represents a rare subset of lung cancer, with specific presentation, and …

… Karima Bouledrak, Pr Nicolas Girard, Dr Chahera Khouatra, Dr Marianne Leveque, Dr fabrice
Piegay, Pr Isabelle Durieu, Dr Raphaëlle Nove-Josserand, Dr Claire Grange, Dr Corinne …

Les carcinomes sarcomatoïdes pulmonaires sont des tumeurs pulmonaires rares appartenant
au groupe des carcinomes bronchiques non à petites cellules, dont ils représentent 2 à 3…